It is recommended for invasive BC patients who are HR+/HER2‐, staged T1‐2, and either lymph node‐negative or with 1–3 metastases.[29] This test evaluates the 10‐year risk of distant metastasis and classifies patients into high or low recurrence risk groups. Here, HR is linked to breast cancer.